XTL Biopharmaceuticals Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 20, 2026, announcing that the company will hold an Extraordinary General Meeting of Shareholders on December 28, 2026.
Key Highlights
- Meeting date: The Extraordinary General Meeting of Shareholders is scheduled for Monday, December 28, 2026 at 4:00 p.m. Israel time.
- Location: The meeting will be held at the offices of the company's attorneys, Amit, Pollak, Matalon & Co., at APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.
- Announcement date: XTL Biopharmaceuticals Ltd. announced the meeting on November 20, 2026.
- Voting options: According to the filing, holders of ordinary shares may vote in person or by proxy at the meeting.
- Signed by: The filing was signed by Noam Band, Chief Executive Officer of XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Schedules December 2026 Extraordinary General Meeting
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB), a foreign private issuer headquartered at 85 Medinat ha-Yehudim St., Herzliya, Israel, disclosed through a Form 6-K that it will convene an Extraordinary General Meeting of Shareholders on December 28, 2026. According to the filing, the meeting is set for 4:00 p.m. Israel time and will take place at the Tel Aviv offices of the company's attorneys, Amit, Pollak, Matalon & Co.
The filing furnishes two exhibits in connection with the meeting. The first, Exhibit 99.1, is described as a Notice and Proxy Statement covering the proposals to be voted upon, the procedure for voting in person or by proxy, and various other details related to the meeting. The second, Exhibit 99.2, is a form of Proxy Card through which holders of ordinary shares may cast votes without attending the meeting in person, according to the filing.
The Form 6-K was submitted for the month of November 2026 under Commission File Number 001-36000. The company files annual reports under Form 20-F, as indicated on the cover page of this report. The filing was signed on November 20, 2026 by Noam Band in his capacity as Chief Executive Officer of XTL Biopharmaceuticals Ltd.
What Was Disclosed
XTL Biopharmaceuticals Ltd. filed a Form 6-K on November 20, 2026, announcing an Extraordinary General Meeting of Shareholders for December 28, 2026, and furnishing a Notice and Proxy Statement and a Proxy Card as exhibits.



Please wait processing your request...